Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized Study Comparing the Efficacy and Safety of Two Doses of Thalidomide (100 mg/Day Versus 400 mg/Day) in the Treatment of Subjects With Refractory or Relapsed Multiple Myeloma.

NCT00657488 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00657488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00657488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized Study Comparing the Efficacy and Safety of Two Doses of Thalidomide (100 mg/Day Versus 400 mg/Day) in the Treatment of Subjects With Refractory or Relapsed Multiple Myeloma.
Lead sponsor
Celgene
Phase
Phase 2/3
Overall status
Completed
Start date
December 1, 2001
Completion date
April 1, 2006
Enrollment
400 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma